Wolf touched on the implications of results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma.
A study of the effect of intravenous immunoglobulin (IVIG) on infections in patients with multiple myeloma receiving daratumumab indicated that hypogammaglobulinemia was nearly universal during treatment, suggesting a role for IVIG.
The director of clinical research in the Center for Cancer Care at White Plains Hospital explained the design of the study which evaluated diabetic versus nondiabetic patients enrolled in the CONNECT Multiple Myeloma Registry.
The expert from the Levine Cancer Institute discussed the findings from an updated analysis of the phase 2 GRIFFIN Trial for patients with newly diagnosed multiple myeloma.
Wolf discussed the decisions to change therapy based on the MRD status of patients with multiple myeloma.
The clinical researcher spoke about what she hopes will occur in multiple myeloma research over the next 5 years.
Wolf discusses the potential for emerging next-generation CAR T-cell treatment and the future of treating patients with multiple myeloma.
The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai discussed exciting treatment options for patients with multiple myeloma that are being presented at ASH this year.